Home > Insider Trading > Filing (0000919574-18-005198)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1634432	Strongbridge Biopharma Plc	SBBP	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1325713	Bruce Kovner	C/O Caxton Corporation 731 Alexander Road, Building #2 Princeton NJ 08540	No	No	Yes	No
1388551	Caxton Corp	731 Alexander Road Building #2 Princeton NJ 08540	No	No	Yes	No
1576081	Cdk Associates, L.l.c.	C/O Caxton Corporation 731 Alexander Road, Building #2 Princeton NJ 08540	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares, $0.01 Par Value	Acquisiton	2018-08-08	360,995	$4.93	6,294,829	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Footnotes

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.878 to $5.00 per share, inclusive. The Reporting Persons undertake to provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price.
These shares represent (a) 5,968,147 Ordinary Shares that are owned directly by CDK Associates, LLC, which is a reporting person, and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation; and (b) 326,682 Ordinary Shares beneficially owned by employees of an affiliate of Caxton Corporation and entities affiliated with such employees and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.